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Abstract
Cannabis has been used for recreational purposes around
the world. It is derived from the plant cannabis sativa which
has various other compounds known as cannabinoids. Most
common form of cannabis used for recreational purpose is
marijuana, which is prepared from dried flowering tops and
leaves. The primary psychoactive component is delta 9tetrahydrocannabinol (δ-9THC), which exerts its
physiological and psychological effects through its
interaction with CB1 and CB2 receptors. Smoking is the
most commonly used method with onset of effects within
minutes after inhalation. Oral ingestion of cannabis has
varied absorption with delayed onset but longer duration of
action. Urine drug screen is the most common method for
detecting cannabis use. Other cannnabionoids such as
cannabidiol have been utilized for medicinal purpose and
research is ongoing to fully understand its role in treatment
of various health conditions. Synthetic cannabis has
emerged as drug of abuse over recent years and poses
greater challenges due to serious physiological and
psychological effects and inability to be detected in
standard screening tests.
Keywords: Cannabis, marijuana, cannabinoids, CB
receptors, CB2 receptors, delta 9-tetrahydrocannabinol
(δ-9THC), synthetic cannabinoids
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Cannabis has been used for recreational purpose
around the world for many decades. Its use however
has increased in recent years among adolescents and
young adults. Much of this increase seems to correlate
with low risk perception (1, 2). The primary
psychoactive constituent of cannabis is delta 9tetrahydrocannabinol (δ-9THC) known to have
various physiological and psychological effects.
Chronic use leads to dependence and behavioral
disturbances (3). Multiple studies have explored
effects of cannabis on various health conditions, but
its medicinal use is currently limited (3, 4). Debate
exits over decriminalization and legalization of
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cannabis with potential to have varied consequences
(5). This paper describes main cannabinoids, their
mechanism of action and metabolism in humans.

and anti-inflammatory properties. Research is
ongoing to understand its role in treatment of various
health conditions (10, 11).

Phyto-cannabinoids

Mechanism of action

Cannabis is derived from a female plant Cannabis
sativa which contains many compounds known as
phyto-cannabinoids or commonly cannabinoids. The
principal
cannabinoids
are
delta
9tetrahydrocannabinol (δ-9THC), cannabidiol (CBD)
and cannabinol (CBN) (4). THC initially isolated in
1964, is a primary psychoactive agent and has been
widely studied (6, 7).Over the years, many new
cannabinoid and non- cannabinoid compounds in the
plant have been discovered (4). The number of
cannabinoids identified since 2005 has increased from
70 to 104. Other known compounds in the plant have
also increased from 400 to 650 (4). The content of
THC varies in different sources and preparations of
cannabis. Its content is highest in the flowering tops
and subsequently declines in the leaves, stem and
seeds of the plant (8). Most common form of cannabis
that is used for recreational purpose is Marijuana with
THC content from 0.5% to 5%. It is prepared from the
dried flowering tops and leaves (6-8). Another form
of cannabis is hashish with THC content 2–20% and
is derived from dried cannabis resin and compressed
flowers (9). The potency of cannabis products has
increase significantly from approx. 3% to 12-16% or
higher (percent THC weight/per dry weight of
cannabis) over the past decades due to sophisticated
cultivation and plant breeding techniques. The
concentration of THC can also reach about 80% using
butane hash oil (4). In the 1960’s and 1970’s, a
cannabis product for example contained about 10 mg
of THC. But, current joint made of other subspecies
of cannabis may contain about 150 mg of THC.
Current generation of cannabis user may be exposed
to higher concentrations of THC as compared to those
who used cannabis decades earlier (8).
Cannabidiol (CBD) is a non-psychoactive
cannabinoid obtained from the plant. Over the years,
it has drawn much attention due to its
pharmacological activity and therapeutic use (10).
CBD is found to have neuroprotective, analgesic,
sedative, anti-emetic, anti-spasmodic, anti- anxiety

Cannabinoids are known to exert their physiological
action through G protein coupled receptors known as
CB1 and CB2. These receptors were initially
identified in 1990s and have been extensively studied
(12). Activation of these receptors leads to inhibition
of adenylyl cyclase resulting in decreased production
of cAMP and changes in ion channel activity.
Through these receptors, cannabinoids hyperpolarize
neurons by closing voltage-dependent calcium
channels and activate potassium channels (13). CB1
receptors are present in both central and peripheral
nervous system. They are mostly present in region of
brain associated with memory, cognition, reward,
anxiety, pain perception, movement (12-14). These
include cortex, hippocampus, olfactory area, basal
ganglia, cerebellum and spinal cord. Few CB1
receptors are found in the brainstem and thus
administration of cannabinoids is not associated with
respiratory depression unlike opioids (8, 13, 14). CB1
receptor activation has also shown to modulate
neurotransmitters in the brain, including glutamate, γamino butyric acid (GABA), opioids, dopamine, and
serotonin, resulting in varied effects (8, 9). Role of
serotonin receptor 5-HT2A in causing some of
specific effects of THC such as memory deficits,
anxiolytic-like effects, and social interaction has been
reported (15). CB2 receptors are present in the cells of
immune system predominantly in the spleen and
macrophages and appear to play role in modulation of
cytokine release and immune cell migration (14).

Endocannabinoids
Endocannabinoids are endogenous compounds
discovered in the 1990s that interact with cannabinoid
receptors and produce similar effects as cannabis (10).
The two main endogenous compounds are
anandamide (from the Sanskrit word ananda, meaning
bliss) and 2-arachidonoylglycerol (2AG) (10). These
are derivative of the fatty acid arachidonic acid
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related to the prostaglandins. Anandamide is partial
agonist for both CB1 and CB2 receptors with CB1
efficacy higher than CB2. It produces similar effects
to δ-9THC, but is less potent and has shorter half-life
due
to
rapid
metabolism
(9,
16).
2Arachidonoylglycerol was originally identified in
intestinal tissue and is found at much higher levels
than anandamide in the brain. 2-AG is thought to be
the main endogenous agonist for both CB1 and CB2
receptors (16). Endocannabinoids also interact with
other G protein coupled receptor and ion channels.
Some of the known ion channel are vanilloid
receptor-type 1 (TRPV1) activated by anandamide.
Other receptors are several types of potassium
channels, alpha7 nicotinic receptors and 5-HT3
receptors (10, 11). The endocannabinoid system
comprised
of
endocannabinoids
and
its
receptors is thought to mediate various physiological
processes and are implicated in health and disease
(16).

Absorption of cannabis
The tetrahydrocannabinol and other cannabinoids
have varied absorption and effects depending on dose,
route of administration and vehicle. Further
physiological factors such as metabolism and
excretion can influence drug concentrations and its
subsequent effects (11). Smoking is most common
and widely used method. After inhalation, THC is
rapidly absorbed through lungs and reaches brain
quickly with physiological and psychological effects
becoming apparent within seconds to minutes (10,
17). The effects then reach a plateau that can last 2–4
h before slowly declining. While, the amount of THC
absorbed is higher with inhalation, the bioavailability
varies according to the depth of inhalation, puff
duration and breath-hold (17). Absorption of THC is
variable when ingested. When taken orally, some of
the THC is degraded by liver due to first pass
metabolism and converted to 11-hydroxy δ-9THC,
which is also a psychoactive agent (10, 17). The
concentration of 11-hydroxy δ-9THC is thus higher in
blood after ingestion than inhalation and may
contribute to some of the psychological effects (17).
With oral ingestion, onset of effect and peak
concentration of THC in blood is much delayed (1-
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2h) (11). Slow gastrointestinal absorption prolongs
the duration of action that may last several hours (8,
9, 11). Other routes of administration for cannabis
such as oro-mucosal, rectal and transdermal have
been explored and studied. These routes of
administration increase bioavailability of THC by
avoiding first pass metabolism in the liver. Such
forms may be beneficial for therapeutic uses but
further research is needed (11).

Distribution
Cannabinoids are highly lipophilic and get distributed
in adipose tissue, liver, lung and spleen (9). Following
assimilation in blood, concentration of THC in plasma
decreases due to peripheral redistribution particularly
in adipose tissues. Sequestration in adipose tissue
prolongs elimination half- life that can last for several
days (8, 11). From the adipose tissue, THC gets
slowly released into the blood stream and other body
compartments including the brain. Cannabinoids also
cross the placenta, entering into fetal circulation and
secreted in breast milk (9).

Metabolism and elimination
THC is metabolized in the liver by microsomal
hydroxylation and oxidation using enzymes of
Cytochrome P 450 Complex generating more than
100 metabolites (18, 19). As a result of hydroxylation,
THC generates a psychoactive compound 11-hydroxy
δ 9_Tetra hydrocannabinol (11-OH-THC). Further,
11-OH-THC is oxidized by microsomal alcohol
dehydrogenase and aldehyde oxygenase to produce
the non-psychoactive metabolite, THCCOOH (11).
The majority of cannabinoids (80-90%) are excreted
within five days as hydroxylated and carboxylated
metabolites (18). The elimination of metabolites is
mostly through feces (65%) and approximately 20%
in urine (17). Among the major metabolites, 11-OHTHC is predominantly excreted in feces and
THCCOOH is excreted in urine mainly as a
glucuronic acid conjugate. This particular metabolite
has been utilized for diagnostic purposes for detection
of cannabis in urine (17).
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Detection and analysis of cannabis

Synthetic cannabinoids

Cannabinoids can be detected in urine, blood, saliva,
hair and nail using various analytical techniques (20).
These techniques are utilized to measure cannabinoids
for research studies, drug treatment and employment
related drug screening. Various chromatographic
techniques such as thin layer chromatography (TLC),
high performance thin layer chromatography
(HPTLC), gas chromatography-mass spectrometry
(GC-MS), high-performance liquid chromatographymass spectrometry (HPLC- MS) have been utilized
for detection and quantitation of cannabis metabolites
(17). The preferred sample for screening is urine to
check for presence of urine metabolites particularly
glucuronic acid conjugate of THCCOOH (20). The
main techniques utilized for urine drug screening are
immunoassay
and
gas
chromatography-mass
spectrometry (GC-MS). Immunoassays are the most
common method for initial screening while GC-MS is
used for confirmation (21, 22). The cut off limit for
cannabis metabolites in immunoassay is 50ng/ml; it is
15 ng/ml for GC-MS. Detection of metabolites in
urine varies depending on frequency and duration of
cannabis use. It can be detected anywhere from 3 days
(single use) up to 30 days or longer (long term heavy
smoker) (22).
Detection of THC and its metabolites is
influenced by various other factors in addition to
sensitivity and specificity of assays. These factors
include route of administration, amount of
cannabinoids consumed and absorbed, body fat
content, rate of metabolism and excretion, time of
specimen collection (9, 20).
There has been growing interest in utilization of
oral fluids as an alternative biological specimen for
detection of drugs in forensic and clinical settings
(23). Studies have shown oral fluids to be simple,
non-invasive method of specimen collection with
advantages of observed specimen collection, making
adulteration difficult. It has shown to have stronger
correlation with blood than urine concentration of
cannabis metabolites and can detect recent exposure
(23). It also offers ease of multiple sample collections
and lower biohazard risk of specimen collection.
Currently, research on oral fluids in ongoing and
further evaluation is needed before implementing it a
drug screening test (23).

Synthetic cannabinoids are a heterogeneous group of
compounds originally synthesized for research
purpose to explore endogenous cannabinoid system
for possible therapeutic use (24). However, these
compounds became drugs of abuse and were
marketed as “designer drugs”. In the 2000s, synthetic
cannabinoids were sold under brand names such as
“spice” and “K2,” labeled as herbal incense. These
became very popular drugs of abuse as they could not
be detected by standard screening tests (25).
The synthetic cannabinoids acts on cannabinoid
receptors and have greater affinity to CB1 than CB2
receptors. Both animal and in vitro studies have
shown that synthetic cannabinoids are 2-100 times
more potent than THC (25). Synthetic cannabinoids
are metabolized in the liver via conjugation and
oxidation pathways and have longer elimination halflife (24, 25). Use of synthetic cannabinoids has
resulted in medical and psychiatric emergencies due
to their intense physiological and psychological
effects. Some of the common adverse effects include
seizures, myocardial infarction, acute renal failure,
anxiety, agitation, psychosis, suicidal ideation, and
cognitive impairment. Long-term or residual effects
are currently unknown (26, 27).
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